tiprankstipranks
Trending News
More News >
ADC Therapeutics Ltd (ADCT)
NYSE:ADCT
US Market
Advertisement

ADC Therapeutics (ADCT) AI Stock Analysis

Compare
375 Followers

Top Page

ADCT

ADC Therapeutics

(NYSE:ADCT)

Rating:54Neutral
Price Target:
$3.50
▲(12.90% Upside)
ADC Therapeutics' overall stock score is primarily impacted by its challenging financial performance, characterized by declining revenues and high leverage. While technical indicators show positive momentum, the valuation remains unattractive due to ongoing losses. The earnings call provided some optimism with strong clinical trial results and an extended cash runway, but restructuring costs and increased net losses are concerns. Corporate events indicate a strategic focus on growth, which is a positive sign.
Positive Factors
Clinical Trials
ADCT released an update on their Phase 1b LOTIS-7 study of Zynlonta + Columvi, which included highly competitive efficacy data.
Financial Performance
ADC Therapeutics recorded a net loss of $0.29 per share—narrower than previously estimated net loss of $0.41 per share.
Financial Strategy
$100M PIPE extends runway into 2028.
Negative Factors
Market Uptake
Risks include slower than anticipated market uptake for ADCT-402.
Regulatory Approval
Risks include the inability to obtain timely approval for ADCT-402 in DLBCL.
Sales Performance
ZYNLONTA's 4Q24 sales fall relative to 3Q24.

ADC Therapeutics (ADCT) vs. SPDR S&P 500 ETF (SPY)

ADC Therapeutics Business Overview & Revenue Model

Company DescriptionADC Therapeutics SA (ADCT) is a biotechnology company focused on the development and commercialization of antibody-drug conjugates (ADCs) for the treatment of hematologic cancers and solid tumors. Operating within the healthcare and pharmaceutical sectors, the company leverages its proprietary ADC technology to create targeted therapies that selectively kill cancer cells while sparing healthy cells. ADC Therapeutics is headquartered in Lausanne, Switzerland, and is committed to advancing its innovative therapies through clinical trials and regulatory approvals.
How the Company Makes MoneyADC Therapeutics primarily makes money through the development and commercialization of its proprietary antibody-drug conjugates. Revenue is generated from partnerships, collaborations, and licensing agreements with other pharmaceutical companies, which may include upfront payments, milestone payments, and royalties on sales. The company also seeks to generate revenue from the sale of its ADC products once they receive regulatory approval. Strategic alliances and collaborations are significant contributors to the company's earnings, allowing ADC Therapeutics to leverage external expertise and resources to advance its product pipeline.

ADC Therapeutics Earnings Call Summary

Earnings Call Date:Aug 12, 2025
(Q2-2025)
|
% Change Since: 15.67%|
Next Earnings Date:Nov 11, 2025
Earnings Call Sentiment Neutral
The earnings call highlighted strong clinical trial results and a solid financial position, with significant potential for future growth. However, this is tempered by restructuring costs and increased net losses.
Q2-2025 Updates
Positive Updates
Promising ZYNLONTA Combination Data
ZYNLONTA in combination with glofitamab showed an overall response rate of 93.3% and a complete response rate of 86.7% across 30 efficacy-evaluable DLBCL patients. 25 of the 26 patients achieving CR remained in CR as of the data cutoff.
Record Cash Position and Extended Runway
Cash and cash equivalents were $264.6 million as of June 30, 2025, up from $194.7 million at March 31, 2025. The cash runway now extends into 2028.
Potential to Transform Lymphoma Treatment
ZYNLONTA has the potential to reach peak revenues of $600 million to $1 billion in the U.S., with opportunities in second line plus DLBCL and indolent lymphomas.
Positive Phase II IIT Data in Marginal Zone Lymphoma
Updated data from the Phase II IIT in marginal zone lymphoma showed an overall response rate of 85% and a complete response rate of 69%.
Negative Updates
Restructuring and Impairment Costs
Incurred $13.1 million in restructuring and impairment costs in Q2 2025, including $6.7 million in employee severance and related benefit costs and $6.4 million in noncash impairment assets.
Net Loss Increase
Reported a net loss of $56.6 million for Q2 2025, compared to a net loss of $36.5 million in Q2 2024, primarily due to restructuring costs and higher R&D expenses.
Workforce Reduction
A strategic plan to reduce global workforce across functions by approximately 30% as part of restructuring efforts.
Company Guidance
During the ADC Therapeutics SA Q2 2025 earnings call, the company reported net product revenues of $18.1 million for the second quarter and $35.5 million for the first half of the year, both slightly exceeding the prior year's figures. Promising clinical data from the LOTIS-7 trial were highlighted, with a 93.3% overall response rate and an 86.7% complete response rate in 30 efficacy-evaluable DLBCL patients. The company plans to expand enrollment to 100 patients at a 150-microgram per kilogram dose, aiming for regulatory discussions and compendia strategies. The LOTIS-5 trial remains on track to reach the prespecified number of progression-free survival events by the end of 2025, with potential peak sales of $200 million to $300 million. ADC Therapeutics completed a $100 million private placement, extending its cash runway into 2028, and announced a strategic plan to streamline operations, including a 30% reduction in global workforce. Overall, the company anticipates ZYNLONTA could reach peak U.S. revenues of $600 million to $1 billion.

ADC Therapeutics Financial Statement Overview

Summary
ADC Therapeutics faces significant financial challenges characterized by declining revenues and margins, high leverage, and negative cash flows. The company must address its operational inefficiencies and improve its financial resilience to stabilize and grow sustainably.
Income Statement
35
Negative
ADC Therapeutics has shown a significant decrease in revenue from 2022 to TTM 2025, with a negative revenue growth rate. The gross profit margin remains relatively high, indicating efficient cost management. However, the company is struggling with negative net and EBIT margins, reflecting ongoing operational and profitability challenges.
Balance Sheet
20
Very Negative
The balance sheet reveals a concerning financial position, with negative stockholders' equity and a high debt-to-equity ratio due to substantial liabilities outweighing assets. The equity ratio is also negative, indicating high leverage and financial instability.
Cash Flow
30
Negative
Cash flow analysis shows a consistent negative free cash flow, with operating cash flow significantly negative compared to net income, suggesting cash burn issues. While financing cash flow is positive, it primarily covers operational cash deficits rather than growth investments.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue70.19M70.84M69.56M209.91M33.92M0.00
Gross Profit63.85M64.89M67.03M205.33M32.52M-1.97M
EBITDA-99.25M-103.71M-146.76M-108.06M-223.72M-219.26M
Net Income-149.84M-157.85M-240.05M-155.80M-230.03M-246.29M
Balance Sheet
Total Assets272.54M321.98M354.78M490.86M617.97M513.69M
Cash, Cash Equivalents and Short-Term Investments194.70M250.87M278.60M326.44M466.54M439.19M
Total Debt334.70M123.00M124.38M117.38M101.75M41.87M
Total Liabilities510.76M524.62M503.03M411.41M451.88M178.19M
Stockholders Equity-238.22M-202.64M-148.25M79.45M166.09M335.50M
Cash Flow
Free Cash Flow-135.40M-124.70M-121.90M-139.09M-239.75M-171.54M
Operating Cash Flow-134.81M-123.83M-118.69M-136.79M-233.38M-168.73M
Investing Cash Flow-590.80K-867.00K-3.22M-2.51M-6.67M-2.83M
Financing Cash Flow95.34M97.05M73.88M-593.00K267.39M494.97M

ADC Therapeutics Technical Analysis

Technical Analysis Sentiment
Positive
Last Price3.10
Price Trends
50DMA
3.00
Positive
100DMA
2.42
Positive
200DMA
2.20
Positive
Market Momentum
MACD
0.05
Negative
RSI
54.83
Neutral
STOCH
79.81
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ADCT, the sentiment is Positive. The current price of 3.1 is above the 20-day moving average (MA) of 2.94, above the 50-day MA of 3.00, and above the 200-day MA of 2.20, indicating a bullish trend. The MACD of 0.05 indicates Negative momentum. The RSI at 54.83 is Neutral, neither overbought nor oversold. The STOCH value of 79.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ADCT.

ADC Therapeutics Risk Analysis

ADC Therapeutics disclosed 57 risk factors in its most recent earnings report. ADC Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

ADC Therapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (65)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
65
Neutral
¥346.28B11.35-1.45%2.36%9.60%-12.35%
54
Neutral
$349.87M123.38%15.73%38.73%
49
Neutral
$260.73M-99.23%-40.10%-16.60%
47
Neutral
$276.96M-32.38%23.24%
46
Neutral
$380.23M-49.72%6.82%
45
Neutral
$197.75M40.36%9.78%98.13%
39
Underperform
$240.13M-38.06%29.16%72.33%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
ADCT
ADC Therapeutics
3.18
0.11
3.58%
HRTX
Heron Therapeutics
1.40
-0.55
-28.21%
SLN
Silence Therapeutics
5.35
-10.85
-66.98%
AVIR
Atea Pharmaceuticals
3.66
-0.24
-6.15%
OLMA
Olema Pharmaceuticals
5.76
-6.19
-51.80%
JBIO
Jade Biosciences
8.23
1.39
20.32%

ADC Therapeutics Corporate Events

Private Placements and FinancingBusiness Operations and Strategy
ADC Therapeutics Announces $100M Private Placement
Neutral
Jun 12, 2025

On June 11, 2025, ADC Therapeutics SA announced a $100 million private placement with institutional investors, selling common shares and pre-funded warrants. This strategic move is aimed at bolstering their financial position and facilitating the company’s focus on expanding ZYNLONTA® and advancing its PSMA-targeting ADC. Concurrently, the company announced a restructuring plan to streamline operations by shutting down its U.K. research facility and reducing its workforce by 30%, with expected completion by September 30, 2025. This restructuring is anticipated to incur one-time pre-tax charges of approximately $6 million to $7 million.

Shareholder MeetingsBusiness Operations and StrategyFinancial Disclosures
ADC Therapeutics Approves Key Proposals at Annual Meeting
Positive
Jun 5, 2025

On June 3, 2025, ADC Therapeutics SA held its annual general meeting where all proposals were approved by shareholders. Key decisions included the approval of financial statements for 2024, discharge of board members from liability, and reelection of directors and auditors. Additionally, amendments to increase share capital for employee participation were sanctioned, reflecting the company’s strategic focus on growth and employee engagement.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 19, 2025